These data accord with the finding that lentiviral gene therapy corrected the alterations of both central and peripheral B-cell tolerance checkpoints and ameliorated B-cell development and functionality in patients with Wiskott-Aldrich syndrome.25, 26 Of note, the engraftment and expansion of gene-corrected B cells expressing WASP could have been favoured by pretreatment rituximab-mediated depletion of B cells, particularly autoreactive B cells, highlighting the key role of this drug in the conditioning of patients with Wiskott-Aldrich syndrome before gene therapy. This evidence concerns the gene WAS and Wiskott-Aldrich syndrome.